SubsidieMeestersTargeting Cancer with ERV Vaccines
InProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors.
Projectdetails
Introduction
InProTher (IPT) is developing a unique immunotherapy – BreakImmune – that effectively targets endogenous retroviruses (HERVs) to treat cancer.
Background on HERVs
HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as:
- Breast (88%)
- Prostate (90%)
- Ovarian (90%)
- Pancreatic (80%)
Thus, HERVs can be a potential target for the immune system to destroy tumor cells.
IPT Technology
IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines. The administration of BreakImmune, the mutated HERVK in Ad19/MVA viral vectors, induces both strong antibody and T-cell immune responses able to destroy cancer cells in multiple cancer types.
Product Overview
Our first product is IPT001, a first-in-class vaccine against solid cancers in combination with checkpoint inhibitors.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 12.179.813 |
Tijdlijn
| Startdatum | 1-7-2022 |
| Einddatum | 31-10-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- INPROTHER APSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment. | ERC POC | € 150.000 | 2022 | Details |
Targeting cancer with mutanome based stem cell vaccineMUTAVAC aims to enhance IPVAC, an innovative cancer immunotherapy leveraging iPSC technology, by uncovering its mechanisms, improving immunogenicity, and paving the way for personalized cancer vaccines. | EIC Pathfinder | € 1.782.000 | 2022 | Details |
Overcoming resistance to immunotherapy: Immunostimulatory tumor-derived extracellular vesicles as multifunctional anticancer agentsIMMUNO-TEX aims to develop tumor-derived immunostimulatory extracellular vesicles to enhance antitumor immunity and overcome resistance to immune checkpoint inhibitors in poorly immunogenic tumors. | ERC STG | € 1.650.778 | 2023 | Details |
Synergistic Antitumor Activity of Microbiome and OMV-based in situ VaccinationThe project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy. | ERC POC | € 150.000 | 2023 | Details |
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.
This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment.
Targeting cancer with mutanome based stem cell vaccine
MUTAVAC aims to enhance IPVAC, an innovative cancer immunotherapy leveraging iPSC technology, by uncovering its mechanisms, improving immunogenicity, and paving the way for personalized cancer vaccines.
Overcoming resistance to immunotherapy: Immunostimulatory tumor-derived extracellular vesicles as multifunctional anticancer agents
IMMUNO-TEX aims to develop tumor-derived immunostimulatory extracellular vesicles to enhance antitumor immunity and overcome resistance to immune checkpoint inhibitors in poorly immunogenic tumors.
Synergistic Antitumor Activity of Microbiome and OMV-based in situ Vaccination
The project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy.